John Ballantyne, Ph.D., was the Co-Founder and Chief Scientific Officer (CSO) of the biologics contract development and manufacturing company (CDMO), Aldevron, from 1998 until his retirement in 2021, where he created the GMP-Source product line. Dr. Ballantyne led collaborative research projects with military scientists in the development of vaccines and passive-based countermeasures to lethal and potentially weaponized viral threats. In his role as CSO, he also led the Aldevron R&D team in developing new methods and products through internal development programs, collaborations, and licensing of new technology. Later in his career, Dr. Ballantyne focused on creating new approaches to “n of 1” manufacturing challenges to expedite traditional processes, lower costs, and allow a new level of autonomy in personalized medicines production.
In his new, co-founded venture, Agathos, a company dedicated to developing biological systems to facilitate better delivery of therapeutic molecules directly to cells, Dr. Ballantyne is focused on enabling ethical pharmaceutical development that will benefit patients, employees, and society as a whole. Dr. Ballantyne holds undergraduate degrees in Pharmacy from the Central Institute of Technology and the University of Otago in New Zealand. He completed his Ph.D. in Pharmaceutical Sciences at North Dakota State University.